» Articles » PMID: 18449822

The Societal Burden of HIV/AIDS in Northern Italy: an Analysis of Costs and Quality of Life

Overview
Journal AIDS Care
Publisher Informa Healthcare
Date 2008 May 2
PMID 18449822
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

This study aims to measure the direct and indirect costs of HIV/AIDS care and quality of life (QoL) of HIV-infected patients in Northern Italy. We conducted a prospective cohort study over 12 months, enrolling a sample of 121 patients with HIV infection from two cities in Northern Italy. Patients were surveyed at baseline and were followed-up at 6 and 12 months. To assess the relationship between costs and stage of disease, patients were categorized into three groups at baseline: "No HAART" (asymptomatic and never before on highly active antiretroviral therapy (HAART)), "Stable HAART" (HAART with mild HIV infection and no prior opportunistic infections) and "HAART failure" (primary HAART regimen was altered because of severe side effects or immunological failure). Direct medical costs were based on utilization of (day) hospital admissions, diagnostic procedures, laboratory tests, clinic visits, consultations and antiretroviral drug use. Indirect costs included production losses due to absence from work, reduced productivity at work and reduced unpaid labour participation. QoL was assessed by visual analogue scale. Parametric regression was used to estimate the expected value and the standard deviation of annual costs per patient. The expected value of total annual costs was 1818 euros and 9820 euros and 12,332 euros, for groups "No HAART", "Stable HAART" and "HAART failure" respectively. We estimated annual expected earnings as 14,994 euros and 10,811 euros and 9820 euros for the same respective groups. The expected value of QoL on a scale of 0-1 in these same patient groups was 0.80, 0.78 and 0.64. We conclude that indirect costs contribute substantially to total costs and are comparable in magnitude to the direct costs excluding antiretroviral drugs. The costs of inpatient care in our cohort were almost negligible compared to total costs. Despite being in treatment, many patients were still gainfully employed and generated substantial expected annual earnings.

Citing Articles

Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.

Schnitzler L, Evers S, Jackson L, Paulus A, Roberts T BMC Public Health. 2022; 22(1):2180.

PMID: 36434561 PMC: 9701033. DOI: 10.1186/s12889-022-14484-z.


Understanding Individual Barriers to HIV Testing Among Undergraduate University Students: Results From a Cross-Sectional Study in Italy.

Licata F, Angelillo S, Nobile C, Di Gennaro G, Bianco A Front Med (Lausanne). 2022; 9:882125.

PMID: 35514754 PMC: 9063657. DOI: 10.3389/fmed.2022.882125.


Analysis of SF-6D Health State Utility Scores: Is Beta Regression Appropriate?.

Kharroubi S Healthcare (Basel). 2020; 8(4).

PMID: 33271844 PMC: 7712516. DOI: 10.3390/healthcare8040525.


Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.

Di Tanna G, Porter J, Lipton R, Hatswell A, Sapra S, Villa G Health Qual Life Outcomes. 2019; 17(1):171.

PMID: 31718662 PMC: 6852901. DOI: 10.1186/s12955-019-1242-6.


Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial.

Thomas R, Burger R, Harper A, Kanema S, Mwenge L, Vanqa N Lancet Glob Health. 2017; 5(11):e1133-e1141.

PMID: 28964756 PMC: 5640509. DOI: 10.1016/S2214-109X(17)30367-4.